Aetna Confirms It Will Cover Provenge
22 June 2010
By David Miller, minyanville.com
Some out there in bio-investor land have argued insurers will
attempt to avoid covering Dendreon's (DNDN) Provenge due to the
price tag. This view is about as accurate as the notion that (and
it comes from the same folks who said) Provenge would never be
approved. That is to say, not very accurate.
The National Comprehensive Cancer Network (NCCN) Compendium listed
Provenge as part of standard therapeutic practice for metastatic,
hormone-refractory prostate cancer within two weeks of
approval. This was a strong signal to doubters that insurance
reimbursement wasn't going to be a tortured process since most
insurers take their cue from compendia like NCCN. The very short
time between drug approval and the NCCN compendia listing is
remarkable and unusual. It's an indication of how active Dendreon
has been over the past several months working the issue of
reimbursement.
Full article
DISCLAIMER
The links and content above are provided for your convenience to provide further information and do not constitute an endorsement by Bavarian Nordic. We have no control over the nature, content and availability of the sites that are being linked to and thus we assume no responsibility for the privacy practices on such websites.
